De-escalated treatment with trastuzumab, pertuzumab and letrozole an effective, chemotherapy-free regimen for patients with hormone receptor-positive, HER-2-, operable breast cancer, according to findings from the PerELISA neoadjuvant study presented at the ASCO Annual Meeting.
“Neoadjuvant trials with chemotherapy plus anti-HER-2 agents consistently showed a lower rate of pathologic complete response in HER-2-positive, hormone receptor-positive vs. HER-2-positive, hormone receptor-negative tumors,” the researchers wrote. “Here, we report the final results of the PerELISA study, aimed to evaluate the efficacy of a de-escalated, chemotherapy-free neoadjuvant regimen in HER-2-positive, hormone-receptor positive patients selected on the basis of Ki67 response after a short course [of] letrozole.”
This activity is supported by an educational grant from Merck & Co., Inc.
At Issue: Melanoma Resource Center
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.